Table IV.

Comparison of published reports of primary breast diffuse large B-cell lymphoma

Reference Study type	N	Median follow-up (years)	EFS/DFS/PFS	OS	CNS relapse
Avilés et al. (2005) Prospective, single centre: Chemo vs RT vs ChemoRT	96	13.8	83% (10-year EFS in chemoRT arm)	76% (10-year OS in chemoRT arm)	11%
Ryan et al. (2008) Retrospective, multicentre	204	5.5	54% (5-year PFS)	63% (5-year OS)	5%
Jeanneret-Sozzi et al. (2008) Retrospective, multicentre	51†	1.8	36% (5-year DFS)	42% (5-year OS)	14%
Yhim et al. (2010)* Retrospective, multicentre	49‡	3.5	65% (5-year DFS)	74% (5-year OS)	10%
Avilés et al. (2012)* Retrospective, single centre	104	6.5	60% (5-year DFS)	53% (5year OS)	NR
Avilés et al. (2007) Retrospective, single centre	32	5.4	75% (3-year EFS)	63% (3-year OS)	0
Current study* Retrospective, multicentre	76	4.5	66% (5-year PFS)	75% (5-year OS)	16%

^†Survival data presented for the 51 cases of high-grade lymphoma, because multiple histologies were included

^‡Survival data presented for the 49 cases that met criteria for primary breast diffuse large B-cell lymphoma, because advanced stage cases were included

^*Included patients treated with rituximab

Abbreviations: CNS: Central Nervous System; DFS: Disease-Free Survival; EFS: Event-Free Survival; NR: Not Reported; OS: Overall Survival; PFS: Progression-free survival; RT: Radiation Therapy.